A myostatin inhibitory antibody combined with insulin, partially rescues the musculoskeletal phenotype of female insulin-deficient diabetic mice.
Saved in:
| Title: | A myostatin inhibitory antibody combined with insulin, partially rescues the musculoskeletal phenotype of female insulin-deficient diabetic mice. |
|---|---|
| Authors: | Bunn RC; Department of Pediatrics and Barnstable Brown Diabetes Center, University of Kentucky, Lexington, KY, United States., Adatorwovor R; Department of Biostatistics, College of Public Health, University of Kentucky, Lexington, KY, United States., Ray PD; Department of Pediatrics and Barnstable Brown Diabetes Center, University of Kentucky, Lexington, KY, United States., Keeble AR; Center for Muscle Biology, University of Kentucky, Lexington, KY, United States., Fry CS; Center for Muscle Biology, University of Kentucky, Lexington, KY, United States., Uppuganti S; Department of Orthopaedic Surgery, Vandebilt University Medical Center, Nashville, TN, United States., Nyman JS; Department of Orthopaedic Surgery, Vanderbilt University Medical Center and Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, United States., Fowlkes JL; Department of Pediatrics and Barnstable Brown Diabetes Center, University of Kentucky, Lexington, KY, United States., Kalaitzoglou E; Department of Pediatrics and Barnstable Brown Diabetes Center, University of Kentucky, Lexington, KY, United States. |
| Source: | Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2025 Jun 12; Vol. 16, pp. 1558740. Date of Electronic Publication: 2025 Jun 12 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101555782 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2392 (Print) Linking ISSN: 16642392 NLM ISO Abbreviation: Front Endocrinol (Lausanne) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
